Evotec SE (FRA:EVTA)

Germany · Delayed Price · Currency is EUR

2.620

-0.020 (-0.76%)

Last updated: Dec 4, 2025, 8:04 AM CET

-37.02% (1Y)

Market Cap	962.15M
Revenue (ttm)	756.33M
Net Income (ttm)	-158.98M
Shares Out	n/a
EPS (ttm)	-0.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	4
Open	2.620
Previous Close	2.640
Day's Range	2.620 - 2.620
52-Week Range	2.420 - 4.540
Beta	n/a
RSI	45.13
Earnings Date	Apr 20, 2026

About Evotec SE

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic disease... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1993

Employees 4,740

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol EVTA

Full Company Profile

Financial Performance

In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.

Financial Statements

News

There is no news available yet.